Edwards Lifesciences Corp (NYSE: EW) on Monday, plunged -0.56% from the previous trading day, before settling in for the closing price of $86.43. Within the past 52 weeks, EW’s price has moved between $60.57 and $96.12.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 10.28% over the last five years. The company achieved an average annual earnings per share of 10.39%. With a float of $591.80 million, this company’s outstanding shares have now reached $601.10 million.
The firm has a total of 19800 workers. Let’s measure their productivity.
Edwards Lifesciences Corp (EW) Breakdown of a Key Holders of the stock
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Edwards Lifesciences Corp is 1.58%, while institutional ownership is 82.59%. The most recent insider transaction that took place on Apr 09 ’24, was worth 79,135. In this transaction CVP, JAPAC of this company sold 857 shares at a rate of $92.34, taking the stock ownership to the 17,488 shares. Before that another transaction happened on Apr 08 ’24, when Company’s CVP, EMEACLA sold 14,400 for $92.32, making the entire transaction worth $1,329,472. This insider now owns 173,849 shares in total.
Edwards Lifesciences Corp (EW) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 10.39% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.34% during the next five years compared to 15.35% growth over the previous five years of trading.
Edwards Lifesciences Corp (NYSE: EW) Trading Performance Indicators
Edwards Lifesciences Corp (EW) is currently performing well based on its current performance indicators. A quick ratio of 2.67 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.41. Likewise, its price to free cash flow for the trailing twelve months is 80.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.32, a number that is poised to hit 0.70 in the next quarter and is forecasted to reach 3.11 in one year’s time.
Technical Analysis of Edwards Lifesciences Corp (EW)
Analysing the last 5-days average volume posted by the [Edwards Lifesciences Corp, EW], we can find that recorded value of 3.73 million was lower than the volume posted last year of 3.84 million. As of the previous 9 days, the stock’s Stochastic %D was 31.86%. Additionally, its Average True Range was 2.12.
During the past 100 days, Edwards Lifesciences Corp’s (EW) raw stochastic average was set at 65.24%, which indicates a significant increase from 14.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 18.93% in the past 14 days, which was lower than the 29.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $90.08, while its 200-day Moving Average is $78.62. Now, the first resistance to watch is $87.06. This is followed by the second major resistance level at $88.18. The third major resistance level sits at $89.14. If the price goes on to break the first support level at $84.98, it is likely to go to the next support level at $84.02. Now, if the price goes above the second support level, the third support stands at $82.90.
Edwards Lifesciences Corp (NYSE: EW) Key Stats
Market capitalization of the company is 51.68 billion based on 601,927K outstanding shares. Right now, sales total 6,005 M and income totals 1,402 M. The company made 1,534 M in profit during its latest quarter, and 369,900 K in sales during its previous quarter.
